Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study - PubMed
3 hours ago
- #clinical trial
- #multiple sclerosis
- #long-term safety
- Ponesimod 20 mg showed sustained efficacy over 5 years in relapsing multiple sclerosis patients in a long-term extension study.
- Safety was acceptable with no new safety signals; common adverse events were observed, but serious events occurred in about 13% of participants.
- Participants continuously on ponesimod had a lower annualized relapse rate compared to those who switched from teriflunomide.
- More participants in the ponesimod-only group achieved no evidence of disease activity (NEDA-3) than the switch group.